Search research articles
Contact Us
Filters
Showing results (41-50 of 57) with videos related to
Page
of 6
Sort By:
Medecine Et Maladies Infectieuses
|
November 3, 2018
Veillonella parvula spondylodiscitis
H Gouze, L Noussair, I Padovano, et al.
Arthritis and Rheumatism
|
November 11, 1999
Intensified-dose (4 gm/m2) cyclophosphamide and granulocyte colony-stimulating factor administration for hematopoietic stem cell mobilization in refractory rheumatoid arthritis
M Breban, M Dougados, F Picard, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
January 15, 1996
T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats
M Breban, J L Fernández-Sueiro, J A Richardson, et al.
European Cytokine Network
|
April 3, 2001
Inducible nitric oxide synthase attenuates chronic colitis in human histocompatibility antigen HLA-B27/human beta2 microglobulin transgenic rats
H S Blanchard, E Dernis-Labous, D Lamarque, et al.
Annals of the Rheumatic Diseases
|
May 14, 2008
Coexistence of spondyloarthropathy and multiple sclerosis: a series of 21 cases
D Wendling, R-M Flipo, M Breban, et al.
Annals of the Rheumatic Diseases
|
October 14, 2015
Patients with ankylosing spondylitis have been breast fed less often than healthy controls: a case-control retrospective study
J Montoya, N B Matta, P Suchon, et al.
Rheumatology (Oxford, England)
|
November 8, 2002
Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study
M Breban, E Vignon, P Claudepierre, et al.
European Cytokine Network
|
July 29, 1998
Effects of murine recombinant interleukin-10 on the inflammatory disease of rats transgenic for HLA-B27 and human beta 2-microglobulin
V Bertrand, S Quéré, R Guimbaud, et al.
Rheumatology (Oxford, England)
|
January 27, 2006
Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up
L Gossec, A Le Henanff, M Breban, et al.
Presse Medicale (Paris, France : 1983)
|
October 16, 1999
[Bone marrow transplantation in the treatment of autoimmune diseases. ISAMAIR Group]
D Farge, M Breban, L Guillevin, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 57) with videos related to
Sort By:
Page
of 6
Medecine Et Maladies Infectieuses
|
November 3, 2018
Veillonella parvula spondylodiscitis
H Gouze, L Noussair, I Padovano, et al.
Arthritis and Rheumatism
|
November 11, 1999
Intensified-dose (4 gm/m2) cyclophosphamide and granulocyte colony-stimulating factor administration for hematopoietic stem cell mobilization in refractory rheumatoid arthritis
M Breban, M Dougados, F Picard, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
January 15, 1996
T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats
M Breban, J L Fernández-Sueiro, J A Richardson, et al.
European Cytokine Network
|
April 3, 2001
Inducible nitric oxide synthase attenuates chronic colitis in human histocompatibility antigen HLA-B27/human beta2 microglobulin transgenic rats
H S Blanchard, E Dernis-Labous, D Lamarque, et al.
Annals of the Rheumatic Diseases
|
May 14, 2008
Coexistence of spondyloarthropathy and multiple sclerosis: a series of 21 cases
D Wendling, R-M Flipo, M Breban, et al.
Annals of the Rheumatic Diseases
|
October 14, 2015
Patients with ankylosing spondylitis have been breast fed less often than healthy controls: a case-control retrospective study
J Montoya, N B Matta, P Suchon, et al.
Rheumatology (Oxford, England)
|
November 8, 2002
Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study
M Breban, E Vignon, P Claudepierre, et al.
European Cytokine Network
|
July 29, 1998
Effects of murine recombinant interleukin-10 on the inflammatory disease of rats transgenic for HLA-B27 and human beta 2-microglobulin
V Bertrand, S Quéré, R Guimbaud, et al.
Rheumatology (Oxford, England)
|
January 27, 2006
Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up
L Gossec, A Le Henanff, M Breban, et al.
Presse Medicale (Paris, France : 1983)
|
October 16, 1999
[Bone marrow transplantation in the treatment of autoimmune diseases. ISAMAIR Group]
D Farge, M Breban, L Guillevin, et al.
Page
of 6